{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:49:03Z","timestamp":1788367743088,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.xphs.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T01:59:39Z","timestamp":1670551179000},"page":"1246-1254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances"],"prefix":"10.1016","volume":"112","author":[{"given":"Jinhui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Daniela","family":"Selaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-0449","authenticated-orcid":false,"given":"Diaa","family":"Shakleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Faustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.12.005_bib0001","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.clinthera.2008.12.002","article-title":"Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum","volume":"30","author":"Chrysant","year":"2008","journal-title":"Clinic Therap"},{"issue":"10, Supplement 1","key":"10.1016\/j.xphs.2022.12.005_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(99)00727-4","article-title":"Angiotensin II receptor blockers: review of the binding characteristics","volume":"84","author":"Siragy","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.xphs.2022.12.005_bib0003","series-title":"FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)","author":"FDA","year":"2019"},{"key":"10.1016\/j.xphs.2022.12.005_bib0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yrtph.2019.01.007","article-title":"Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products","volume":"103","author":"Snodin","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2022.12.005_bib0005","series-title":"Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry","year":"2021"},{"key":"10.1016\/j.xphs.2022.12.005_bib0006","series-title":"Combined Direct Injection N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS\/MS","year":"2019"},{"key":"10.1016\/j.xphs.2022.12.005_bib0007","series-title":"Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS\/MS","year":"2019"},{"key":"10.1016\/j.xphs.2022.12.005_bib0008","series-title":"A Retrospective Database Analysis of Prescribing Patterns for Specific Angiotensin Receptor Blockers","author":"Saira","year":"2020"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.005_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0300-483X(82)90093-2","article-title":"Calculations and measurements on the volatility of N-nitrosamines and their aqueous solutions","volume":"23","author":"Klein","year":"1982","journal-title":"Toxicology"},{"issue":"21","key":"10.1016\/j.xphs.2022.12.005_bib0010","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1021\/ac202017c","article-title":"Evaluation of a high-throughput online solid phase extraction-tandem mass spectrometry system for in vivo bioanalytical studies","volume":"83","author":"Jian","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.xphs.2022.12.005_bib0011","doi-asserted-by":"crossref","first-page":"e9273","DOI":"10.1002\/rcm.9273","article-title":"An advanced automation platform coupled with mass spectrometry for investigating in vitro human skin permeation of UV filters and excipients in sunscreen products","author":"Zhang","year":"2022","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.xphs.2022.12.005_bib0012","year":"2019"},{"key":"10.1016\/j.xphs.2022.12.005_bib0013","series-title":"ASMS 2020 Annual Conference Poster #TP343","article-title":"Ultrafast analysis of nitrosamines using SPE-QQQ","author":"Truempi","year":"2020"},{"key":"10.1016\/j.xphs.2022.12.005_bib0014","series-title":"Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs","year":"2019"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.005_bib0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mas.20298","article-title":"An overview of matrix effects in liquid chromatography-mass spectrometry","volume":"30","author":"Trufelli","year":"2011","journal-title":"Mass Spectrom Rev"},{"key":"10.1016\/j.xphs.2022.12.005_bib0016","series-title":"Combined Direct Injection N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Impurity Assay by GC\/MS","year":"2018"},{"key":"10.1016\/j.xphs.2022.12.005_bib0017","series-title":"Combined N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Impurity Assay by GC\/MS-Headspace","year":"2019"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:08Z","timestamp":1758361208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922005688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0022354922005688"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.005","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}